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Abstract
Although highly active antiretroviral therapy (HAART) has greatly improved the life expectancy of HIV/AIDS patients,
the treatment is not curative. It is a global challenge which fosters an urgent need to develop an effective drug or
neutralizing antibody delivery approach for the prevention and treatment of this disease. Due to the low density of
envelope spikes with restricted mobility present on the surface of HIV virus, which limit the antibody potency and
allow virus mutation and escape from the immune system, it is important for a neutralizing antibody to form bivalent
or multivalent bonds with the virus. Liposome constructs could fulfil this need due to the flexible mobility of the
membrane with its attached antibodies and the capacity for drug encapsulation. In this study, we evaluated the
neutralization activity of a range of liposome formulations in different sizes coated with anti-gp120 llama antibody
fragments (Vhhs) conjugated via either non-covalent metal chelation or a covalent linkage. The non-covalent construct
demonstrated identical binding affinity to HIV-1 envelope glycoprotein gp120 and neutralizing ability for HIV virus as
free Vhh. Although covalently linked Vhh showed significant binding affinity to gp120, it unexpectedly had a lower
neutralization potency. This may be due to the comparability in size of the viral and liposome particles restricting
the number which can be bound to the liposome surface so involving only a fraction of the antibodies, whereas
non-covalently attached antibodies dissociate from the surface after acting with gp120 and free the remainder to
bind further viruses. Covalently conjugated Vhh might also trigger the cellular uptake of a liposome-virion complex. To
explore the possible ability of the antibody-coated liposomes to have a further function, we encapsulated the
hydrophobic antiviral drug dapivirine into both of the non-covalently and covalently conjugated liposome
formulations, both of which revealed high efficacy in reducing viral replication in vitro. Thus, dual function
liposomes may lead to a novel strategy for the prophylaxis of HIV/AIDS by combining the neutralizing activity
of Vhh with antiviral effects of high drug concentrations.
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Background
Human immunodeficiency virus (HIV), responsible for
the acquired immunodeficiency syndrome (AIDS), is a
lentivirus belonging to the retrovirus family. Infection
causes extensive destruction of T-helper cells, macro-
phages, dendritic cells and other cellular components asso-
ciated with cell-mediated immunity, eventually leading to
AIDS [1, 2]. As a consequence, HIV-infected patients are
more susceptible to opportunistic infections [3]. At present,
HIV-1 and HIV-2 are the two known types of HIV [4].
HIV-1 is more pathogenic and transmissible and is mainly
responsible for the global AIDS pandemic [4]. HIV infec-
tion has continued spreading by the transfer of body fluids
due to exposure to blood or blood products, by homo- or
heterosexual contact, or prenatally from mother-to-child.
Since the start of the epidemic, around 78 million people
have become infected with HIV and 35 million people have
died of AIDS-related illnesses according to the global statis-
tical report from UNAIDS in 2016. In addition, 2.1 million
people became newly infected with HIV and 36.7 million
people were living with HIV globally in 2015.
Currently, the major means of efficient management
of HIV and prevention of its progression towards AIDS
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is highly active antiretroviral therapy (HAART), which
combines a minimum of three antiretroviral drugs from
at least two classes. These include nucleoside reverse
transcriptase inhibitors (NRTIs), non-nucleoside reverse
transcriptase inhibitors (NNRTIs), protease inhibitors
(PIs), fusion inhibitor, integrase inhibitors and/or entry
inhibitors [5]. Although the therapy has improved long-
term survival rate, there are associated toxic side effects
and emergence of multi-drug resistance. Furthermore,
there is a limited access to anti-HIV drugs in the devel-
oping countries due to their high costs [6]. Clearly, there
remains an urgent demand for an effective and low-cost
system for prophylaxis and treatment of HIV infection.
The challenge of developing an effective vaccine or
entry-inhibitor drug for HIV infection lies in the rapid
mutation of the glycoproteins comprising gp120 and
gp41 and the structural features that facilitate antibody
evasion [7–13]. Another recent explanation is the spatial
arrangement of the envelope spikes on HIV virus, which
contributes to its ability to escape the neutralization by
antibodies [14]. As is known, most neutralization activities
can be attributed to antibody-antigen interactions and the
avidity resulting from bivalent binding between two Fabs
and two physically linked antigens greatly increase the
neutralization potency of the antibody [15–17]. The pub-
lished studies indicated that there are 4 to 35 spikes per
HIV virus particle [18–22] with very restricted mobility
[23, 24]. This makes the antibody cross-linking very un-
likely because the hinge (10–15 nm) between the two Fabs
is not long enough to reach the two spikes randomly dis-
tributed on the surface of the virus. When the anti-HIV
antibody b12 was tested as an IgA, IgM or IgG, equivalent
neutralization potency was observed [14]. Actually, a
number of studies have demonstrated that neutralizing
antibodies against HIV cannot take the advantage of avid-
ity effects resulting from the IgG cross-linking epitopes on
the surface of virus [15–17], while antibodies have been
shown to bind bivalently to other viruses comprising
closely spaced epitopes [25, 26].
Liposomes are artificially prepared vesicles composed
of a lipid bilayer and have been used extensively for drug
delivery due to their unique properties [27]. Liposomes
are also platforms for the development of multivalent
antibody constructs by coupling antibody molecules onto
liposome membranes. Chiu et al. have demonstrated that
the antibody potency was increased 25-fold by employing
the multivalent liposome formulation [28], which even
induced cascade effects by cross-linking the antibody
complex [29].
Recently, llama heavy-chain antibody fragments (Vhh),
which compete with surface CD4 for binding to the
HIV-1envelope glycoprotein, have been described as po-
tent cross-clade HIV-1 candidate microbicides [30, 31].
Such Vhh would be excellent candidates for multivalent
liposome platform due to their specificity, high stability
and low production cost [31, 32]. Moreover, these anti-
body fragments showed very efficient ability to penetrate
human tissue by diffusing into the mucosal layer when
placed in a vaginal ring [31].
In this study, multivalent liposomal antibody constructs
were developed by grafting Vhh (J3), which achieves broad
and potent neutralization of HIV-1 via interaction with the
CD4-binding site of HIV-1 env [33], onto the liposome
membrane via either non-covalent metal chelation or a co-
valent linkage. The neutralization potency of multivalent
presentation of these fragments by liposomes was analyzed
by antiviral assays with TZM-bl cells. The results indicated
that the avidity of the Vhh was significantly increased while
the neutralization potency was compromised when the
Vhh was covalently conjugated to the lipid. The additional
ability of the liposome construct to effectively deliver
dapivirine, a potent non-nucleoside reverse transcriptase
inhibitor presently being developed as a vaginal HIV
microbicide, was further investigated.
Methods
Materials
Soy phosphatidylcholine (PC), 1,2-dioleoyl-sn-glycero-3-
[(N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl]
(18:1 DGS-NTA(Ni)) and 1,2-distearoyl-sn-glycero-3-phos-
phoethanolamine-N-[maleimide(polyethylene glycol)-2000]
(malDSPE-PEG2000) were purchased from Avanti Polar
Lipids. Methoxypolyethyleneglycol-di-stearoyl-phosphatidyl-
ethanolamine (DSPE-PEG2000, with mPEG MW2000Da)
was obtained from Genzyme. Cholesterol (Chol), PBS and
Sephadex G25 and G50 were purchased from Sigma.
Acetone, methanol and dichloromethane were from Fisher
Scientific. RPMI1640, L-glutamine, penicillin-streptomycin
and foetal bovine serum (FBS) were from Invitrogen Life
Technologies. Dulbecco’s minimum essential medium
(DMEM) was purchased from Lonza. Vhhs, the variable
region fragment of single heavy-chain llama antibodies,
including J3 and lab5, were purchased from Quality in
Antibodies (Netherlands). Dapivirine, a non-nucleoside re-
verse transcriptase inhibitor (NNRTI), was kindly provided
by the authors Prof. Guido Vanham and Dr. Kevin Arien.
CN54 gp140 was kindly provided by Prof. Robin Weiss
from University College London.
Cells, Virus and Reagents
TZM-bl cells (obtained through the NIH AIDS Research
and Reference Reagent Program, Germantown, MD)
were used for the evaluation of the anti-HIV activity of
free and liposome conjugated Vhh with and without
dapivirine. TZM-bl cells express high densities of CD4,
CCR5 and CXCR4. They contain a luciferase reporter
gene under control of HIV LTR, which will be tran-
scribed and translated into luciferase protein, if the cells
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get infected with HIV and start producing Tat. TZM-bl
cells were cultured in DMEM supplemented with 10 %
heat-inactivated FBS and 50 μg gentamicin/ml medium,
at 37 °C in a humidified 7 % CO2 environment. Cells
were split twice a week and plated at 106 cells in tissue
culture flasks and at 104 cells/well in 96-well plates.
The subtype B CCR-5 using reference HIV-1 strain
Ba-L was obtained from the NIH AIDS Research and
Reference Reagent Program, Germantown, MD. It was
grown and titered in human activated peripheral blood
mononuclear cells (PBMC). PBMC were isolated from
buffy coats from HIV-seronegative blood donors (provided
by the Antwerp Blood Transfusion Centre) using Ficoll
density gradient centrifugation. PBMC were stimulated for
48 h with 2 μg/ml of phytohemagglutinin (PHA) (Remel,
Kent, UK) in RPMI 1640 medium containing 10 % FBS,
50 μg/ml gentamicin and 2 μg/ml polybrene (Sigma-
Aldrich, Bornem, Belgium). Subsequently, PBMC were
activated for 24 h with 1 ng/ml of interleukin-2 (IL-2)
(Gentaur, Brussels, Belgium) in RPMI 1640 medium
supplemented with 10 % FBS, 50 μg/ml gentamicin, 2 μg/
ml polybrene and 5 μg/ml hydrocortisone (Calbiochem,
Leuven, Belgium). PHA, IL-2 activated PBMC.
Liposome Preparation
Liposome compositions used in this study with diame-
ters in brackets were as follows: (a) lipo1 (200 nm), PC/
Chol/DSPE-PEG2000/18:1 DGS-NTA in proportions
65/33/1/1 mol%; (b) lipo2 (100 nm), PC/Chol/DSPE-
PEG2000/18:1 DGS-NTA in proportions 65/33/1/1 mol%
and (c) lipo3 (100 nm), PC/Chol/DSPE-PEG2000/mal-
DSPE-PEG2000 in proportions 65/33.5/0/1.5 mol%. Briefly,
the lipids with or without dapivirine were dissolved in
methanol: dichloromethane 1:2 (v/v) at room temperature.
The lipid mixtures were deposited on the side wall of a
rotary glass vial by removing the solvent with nitrogen.
The resulting dried lipid films were hydrated in 10-mM
sodium phosphate buffer pH 7.4. This process led to the
spontaneous formation of pegylated liposomes. The lipo-
somes were then extruded through 0.2 or 0.1 μm Anotop
10 filters (Whatman). Excess dapivirine was removed on a
Sephadex G25 column [34].
J3 is a neutralizing Vhh, while lab5 is an irrelevant
Vhh (irr-Vhh). J3 and lab5 were polyhistidinylated (J3-
His and lab5-His) for the non-covalent attachment to
liposomes via nitrilotriacetic acid (NTA) linkage. Mean-
while another form of J3 (J3-cys) with extra cysteine in
the C-terminus was generated for covalent conjugation
to liposomes via interaction with a maleimide group.
Vhhs were produced as described before [31]. Non-
covalent immunoliposomes were produced by mixing
Vhh-His with the liposome suspension in a 1:10 M ra-
tio at room temperature for 1 h on a bench roller. Free
thiol groups were generated by incubating J3-cys with
10 mM DTT for 30 min at room temperature. Covalent
immunoliposomes were prepared via interaction be-
tween J3-cys and maleimide-derivatized lipid inserted
in lipo3. The mixture of J3-cys and liposomes with the
maleimide group was allowed to conjugate at room
temperature overnight. Unreacted maleimide groups
were subsequently saturated by adding cysteine. The
immunoliposomes were purified by running through a
Sephadex G50 column to remove excess cysteine or/
and unbound protein.
Characterization of Liposomes
The phospholipid, mainly PC, in the liposome was quan-
tified by the Stewart assay [34]. The number of lipo-
somes per ml was estimated by assuming there were
80,000 phospholipid molecules per liposome of 100 nm
or 320,000 phospholipid molecules per liposome of 200-
nm diameter [35]. The mean particle size distribution
and polydispersity index of liposome suspensions were
determined by dynamic light scattering in a Malvern
Zetasizer Nano-2S (Malvern Instruments, Malvern, UK).
The buffer for zeta potential is MilliQ water pH 7. The
stability of liposomes was evaluated by storing the lipo-
somes at 4 °C for 1 month, and samples were taken for
size measurement.
SDS-PAGE was employed to confirm the conjugation
of Vhh to the liposomes. Fluorescamine was used to
quantify the protein conjugated to liposomes [36]. Fluor-
escamine is a non-fluorescent compound, which reacts
rapidly with primary amines in proteins, such as the ter-
minal amino group of peptides and the ε-amino group
of lysine, to form highly fluorescent moieties. Basically,
the liposome suspension was diluted 1:20 in PBS pH 7.
An aliquot of 25 μl of 2 mg/ml fluorescamine was added
to a total assay volume of 100-μl diluted liposome suspen-
sion. The fluorescence was measured at ex 390 nm/em
475 nm with a cut-off at 455 nm, and the background was
subtracted. The concentration of conjugated protein was
calculated by comparison with standard samples of the
same protein. The concentration of dapivirine in lipo-
somes was determined by measuring the absorbance at
310 nm after incubating the liposomes in ethanol [37, 38].
Enzyme-Linked Immunosorbent Assay
An enzyme-linked immunosorbent assay (ELISA) was
carried out to determine the interaction between liposome-
linked Vhh and gp140 which is a derivative of gp160 that
can be cleaved into gp120 and gp41. Briefly, 1 μg/ml CN54
gp140 was coated at 4 °C overnight on 96-well Maxisorp
plates (NUNC, Denmark). After blocking with 200 μl/well
Microwell Blocking Buffer with Stabilizer (Rockland), serial
dilutions of immunoliposomes in PBS pH 7, free Vhh and
negative control liposomes coated with irr-Vhh (lab5) were
added to the plates for 1 h. After three washes with PBS,
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anti-myc-horse radish peroxidase (HRP) (Roche), which
targets the myc-tag in Vhh, was diluted 1:1000 in HRP
Conjugate Stabilizer (Rockland) and added to detect the
bound Vhh. 3,3′,5,5′-Tetramethylbenzidine liquid (Sigma)
substrate was added and left to develop for 30 min at room
temperature; after which, the reaction was stopped with
2 M H2SO4. Absorbance of the product was measured at
450 nm.
In Vitro Cytotoxicity
Human cancer cells, Hela cells (Sigma-Aldrich, UK), were
cultured in 96-well plates overnight and treated with differ-
ent concentrations of liposomes for 48 h. Medium was then
removed from the plates, and the cells washed twice with
PBS. Fifty microlitres of 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) was added per well.
Cells were incubated for 30 min at 37 °C with 95 % O2 and
5 % CO2. MTT was removed carefully before 100-μl pro-
panol was added per well to dissolve crystals and incubated
for at least 30 min. The absorbance of this coloured solu-
tion was quantified by measuring at a wavelength of
570 nm by FLUOstar Omega (BMG Labtech, Aylesbury,
UK). Each treatment was conducted in triplicate.
Antiviral Assays for Antibody-Mediated Neutralization
and Effectiveness of Liposomal Dapivirine Drug Delivery
The antiviral activity of the compounds was determined
by pre-incubating 104 TZMbl cells/well in a 96-well
plate for 2 h at 37 °C and 7 % CO2 to maintain the opti-
mal pH with or without a serial dilution of compounds.
Next, 200 TCID50 of HIV-1 BaL virus was added to each
well, and cultures were incubated for 48 h before luciferase
activity was quantified. To this end, 120 μL of supernatant
was removed, 75 μl of the luciferase substrate Steadylite
(Perkin Elmer, Life Sciences, Zaventem, Belgium) was
added to the wells, and the plates were incubated at room
temperature on an orbital shaker for 10 min. Next, the
luciferase activity was measured using a TriStar LB941
luminometer (Berthold Technologies GmbH & Co.
KG., Bad Wildbad, Germany) and expressed in relative
light units (RLU).
Each compound was tested in triplicate and each ex-
periment was repeated in three independent runs. Anti-
viral activity was expressed as the percentage of viral
growth compared to the control and plotted against the
compound concentration. Next, non-linear regression
analysis was used to calculate the EC50, using GraphPad
Prism 5.03 using non-linear regression (GraphPad Software,
San Diego, CA, USA).
Results
Liposome Preparation and Characterization
Three groups of liposome suspensions: lipo1, lipo2 and
lipo3, were prepared to investigate whether the size or
Vhh density of the liposomes will contribute to the
neutralization efficiency of the liposomes for HIV virus.
Lipo1 was of 200-nm diameter while lipo2 and lipo3
were of 100-nm diameter. His-tagged Vhh (J3-His and
lab5-His) were conjugated to lipo1 or lipo2 by inter-
action with the nickel-chelating lipid 18:1 DGS-NTA-Ni
which was incorporated into the liposome bilayer (Fig. 1a).
The sulphydryl-reactive lipid (malDSPE-PEG2000) in lipo3
allowed covalent attachment of the reduced J3-cys to the
liposome (Fig. 1b). Immunoliposomes were then purified
by size exclusion chromatography to remove the unbound
Vhh and impurities. The conjugation and purification
were successful in all cases, and the resulting products
were analyzed by SDS-PAGE (Fig. 2). The conjugated
Vhhs gave bands of higher molecular weight than the free
Vhhs, and this was due to the contribution of the conju-
gated lipids including 18:1 DGS-NTA-Ni or malDSPE-
PEG2000. More than 95 % of the Vhh was shown to be
conjugated to the liposomes by the fluorescamine method
described above [34, 36]. The density of Vhh on liposome
surfaces was shown in Table 1.
Immunoliposomes with or without NNRTI dapivirine
were produced to investigate whether conjugated Vhh
could show higher avidity to antigen and improve the ef-
ficacy of Vhh in HIV viral inhibition, as compared to
free Vhh. Dapivirine was dissolved in the solvent with
lipid mixture when formulating the liposomes. Unincor-
porated dapivirine was removed by size exclusion chro-
matography, and the concentration of dapivirine was
determined by UV spectrometry.
The final immunoliposomes were characterized, and
the data was shown in Table 1. Phospholipid (PC) was
detected in the liposomes by Stewart assay. It was esti-
mated to result in approximately 160 Vhh molecules per
200-nm liposome or 95–125 Vhh molecules per 100-nm
liposome on the basis that one 100-nm liposome contains
80,000 phospholipid molecules and one 200-nm liposome
contains 320,000 phospholipid molecules [29, 35].
This resulted in similar Vhh density on the surface of
the liposomes.
PEGylated liposome suspensions were prepared by the
lipid film rehydration method [34] and extrusion tech-
nique, with a final mean diameter of 200–230 nm or
120–140 nm (polydispersity index of 0.1–0.2). The nega-
tive charge of the liposome formulations were attributed
to the DSPE-PEG2000 or malDSPE-PEG2000which ac-
counts for 1–1.5 % mol of the lipid. The liposomes were
stable for at least 1 month, with no significant change in
size or charge (Fig. 3).
In Vitro Cytotoxicity of the Liposome
Potential cytotoxicity of the liposomes was estimated
from cell viability relative to control Hela cells treated
with medium only. MTT assay demonstrated that cell
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viability was between 80 and 120 % in relation to the
control samples (Fig. 4). One-way ANOVA statistical
analysis showed there is no evidence of liposome toxicity
at concentrations up to 1 mg/ml (p > 0.05).
Analysis of Binding of Liposomal Vhhs to Recombinant
HIV gp140 by ELISA
As Vhh competed with soluble CD4 (sCD4) for binding
to gp120 [32], an ELISA assay was carried out to deter-
mine whether the Vhh conjugated to liposomes showed
compromised binding affinity or increased avidity to
gp140 (CN54). Liposome-linked J3 was compared with
the free J3 at the same concentrations, together with the
irrelevant Vhh (lab5-His) and liposome-coated the same
irrelevant Vhh as negative controls. J3-His and J3-cys
revealed similar binding affinities for gp140 as expected
(Fig. 5). No improved or compromised affinity was ob-
served for lipo1-J3 and lipo2-J3 compared to free J3-His,
implying size differences are not influencing the avidity
despite similar Vhh densities on the liposome surfaces.
Meanwhile, one-way ANOVA statistical analysis showed
that J3 conjugated to lipo3 demonstrated much higher
avidity to gp140 than free J3-cys (p < 0.001), indicating
covalent attachment greatly facilitated J3 interacting with
Fig. 1 Structural basis of conjugation. a Non-covalent ligation between Vhh-His and nickel-chelating lipid 18:1 DGS-NTA-Ni. b Covalent ligation
between Vhh-cys and malDSPE-PEG2000 lipid
Fig. 2 Vhh and conjugated Vhh in liposomes analyzed by SDS-PAGE. Lanes: 1, molecular weight marker; 2, J3-His; 3, lipo1-J3; 4, lipo2-J3; 5, lab5;
6, lipo1-lab5; 7, lipo2-lab5; 8, J3-cys and 9, lipo3-J3
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gp140. In contrast, irrelevant negative controls demon-
strated no binding to gp140.
Characterization of Neutralizing Antibody by Antiviral
Assay
The neutralization activity of liposomal Vhhs and free
Vhhs for HIV virus was evaluated by subsequent incuba-
tion with TZM-bl cells. Lipo1-J3 and lipo2-J3 revealed
similar potencies for neutralization compared to free J3.
Surprisingly, lipo3-J3 only provided 60 % of viral inhib-
ition at J3 concentration of 286 ng/ml, whereas lipo1-J3
and lipo2-J3 inhibited approximately 90 % of viral growth
at the same concentration (Fig. 6a). No viral growth reduc-
tion was observed for control liposomes, liposomes coated
with irrelevant Vhhs or free Vhhs alone. There was no
significant difference in neutralizing activities between
lipo1-J3 and lipo2-J3 compared to free J3-His (Fig. 6b),
revealing no contribution from the size differences.
However, covalently conjugated J3 (lipo3-J3) had a sig-
nificantly higher EC 50 (Fig. 6b), indicating less potency
for neutralization than non-covalently attached J3 or
free J3. The result is unexpected because the ELISA
data revealed significantly increased binding affinity of
lipo3-J3 to gp140 which should contribute to the
neutralization activity of conjugated J3.
Comparison of Antiviral Effects of Liposomal Dapivirine
with Free Dapivirine
We compared the antiviral effects of different formula-
tions of liposomal dapivirine with free dapivirine. The
dose-response curves indicated increased antiviral effect
of liposomal dapivirine compared with free dapivirine,
Table 1 Characterisation of the immunoliposomes
Liposome PC conc. (mg/ml)a Dapivirine (μM) No. of Vhh molecules per liposome Vhh (μg/ml) Diameter (nm)a Zeta potential (mV)a
Lipo1-lab5 11.937 ± 0.001 – 160 126.3 228.0 ± 1.0 −45.0 ± 0.9
Lipo1-J3 11.708 ± 0.008 – 160 118.4 223.4 ± 4.5 −37.4 ± 0.5
Lipo2-lab5 5.974 ± 0.005 – 95 150.0 130.9 ± 1.4 −38.7 ± 0.7
Lipo2-J3 6.149 ± 0.003 – 108 159.9 131.2 ± 1.9 −38.5 ± 0.2
Lipo2-dapi 6.478 ± 0.001 6.5 – – 122.9 ± 1.8 −46.0 ± 0.9
Lipo2-dapi-J3 5.548 ± 0.002 5.5 125 169.6 123.4 ± 1.8 −38.5 ± 0.4
Lipo3 control 7.573 ± 0.003 – – – 130.9 ± 1.7 −42.5 ± 0.4
Lipo3-J3 6.456 ± 0.004 – 121 168.2 142.2 ± 3.2 −36.4 ± 0.4
Lipo3-dapi 6.675 ± 0.003 6.7 – – 128.2 ± 2.6 −41.7 ± 0.5
Lipo3-dapi-J3 6.806 ± 0.001 6.8 108 157.0 139.1 ± 1.8 −37.8 ± 0.6
Dapi: dapivirine
aData are means ± standard deviations of three replicate measurements in one representative experiment of three independent experiments
Fig. 3 Diameter and zeta potential of the liposome formulations over 1-month period. Data are means ± standard deviations of three replicate
measurements in one representative experiment of at least two independent experiments. Using unpaired t test (p > 0.05), no significant change
in diameter or zeta potential of liposomes was observed after 1-month storage at 4 °C. Dapi: dapivirine
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although no significant difference was observed between
lipo2 and lipo3 with or without neutralizing Vhhs (Fig. 7a).
Furthermore, there was approximately 76 % of viral growth
at a concentration of 1-nM free dapivirine, whereas
only 50–56 % of viral growth was detected with liposomal
dapivirine at this concentration. Calculated EC50 (Fig. 7b)
confirmed that liposomal dapivirine is more effective than
free dapivirine in inhibiting HIV virus. However, the anti-
viral effects were dominated by dapivirine since no differ-
ence was observed between the liposome preparations
with or without neutralizing J3.
Discussion
The treatment of HIV remains a serious challenge due
to the high genetic variation of the virus and associated
toxic side effects of the antiviral drugs. HIV-1 neutraliz-
ing antibodies have been considered to be critical for
vaccine development and prevention of HIV infection.
Liposomes provided another approach shown to have
potential for HIV prophylaxis [39]. In the present study,
a combined platform with both liposome and antibody
fragments was developed to investigate the antiviral effi-
ciency of the multivalent liposomal formulation.
Previous studies have demonstrated that Vhhs produced
by llamas (lama glama) exhibited comparable affinity and
specificity for gp120 to conventional immunoglobulins
despite their much smaller size. This smaller size of Vhhs
is an advantage over conventional immunoglobulins as it
has been shown to reduce their immunogenicity [33]. In
particular, J3 Vhh, which achieved broad and potent
neutralization of HIV-1 via interaction with the CD4-
binding site, neutralized 96 of 100 tested HIV-1 strains
and chimeric simian-HIV strains with HIV subtypes B and
C env [33]. Unlike most of the enveloped viruses which
express large numbers of closely spaced spikes on the sur-
face, HIV virus has a low spike surface density (4 to 35
spikes) and the arrangement of these spikes is likely to be
static over the time periods relevant to neutralization [14].
Therefore, the location and arrangement of the neutraliz-
ing Vhhs on the liposome surfaces is critical for their
interaction with the virus particles.
To optimize the size of the liposomal platform, J3 was
non-covalently conjugated to the surface of two lipo-
some formulations with diameters of 100 or 200 nm,
each with approximately the same Vhh densities. Metal
chelation via NTA has been employed to attach peptide
and protein antigens to liposomes to compare with cova-
lent linkage for their ability to elicit antibody responses
[40]. Pegylated liposomes were employed to ensure the
stability and minimal immunogenicity of the platform.
To check that J3 was available and not masked by the
PEG coating on the liposome surface, appropriate access
of J3 to gp140 was verified by ELISA (Fig. 5). The identi-
cal binding curves demonstrated that lipo1-J3 and lipo2-
J3 bound to gp140 with the same avidity as free J3,
showing that the different geometrical location of J3 on
the surface of spherical liposomes did not compromise
its interaction with gp140. Surprisingly, no enhanced
avidity was observed for these liposomal J3 constructs
compared to free J3. This may be due to the charge on
the nickel-histidine complex which would inhibit close
association of the J3 antibody fragments to generate
multivalent attachment to the gp140 on ELISA surface.
This presumption is confirmed by the neutralization
results indicating lipo1-J3 and lipo2-J3 inhibited HIV
infection in a dose-response manner similar to free J3
Fig. 4 Cell viability of Hela cells after 48 h incubation with control
liposomes or immunoliposomes. No significant difference in cell
viability was observed against the media only treatment from one-way
ANOVA (p > 0.05). Data are means ± standard deviations of three
replicate measurements in one representative experiment of at
least two independent experiments. Dapi: dapivirine
Fig. 5 The binding of free J3/J3 linked to liposomes to recombinant
gp140 (CN54) was compared in ELISA. Gp140 was immobilized on
the plate, and Vhh was detected with anti-myc-HRP. Irrelevant Vhh
(lab5) and liposome-irrelevant Vhh were included as negative
controls. Values are means ± standard deviations of three replicate
measurements in one representative experiment of three independent
experiments. *From one-way ANOVA, significant differences were
observed (p < 0.001) between lipo3-J3 and the other liposome
formulations or free Vhhs
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in antiviral assay (Fig. 6). There was no significant differ-
ence in the EC50 between lipo1-J3, lipo2-J3 and free J3,
suggesting no improved antiviral potency for the non-
covalently anchored Vhh independent of liposome sizes.
J3-cys was then covalently attached to liposomes to
produce lipo3-J3 (Fig. 1). One hundred-nanometre diam-
eter liposomes were used for economic reasons and since
liposomes of this size are broadly applied as drug delivery
system [41, 42]. The binding curves for lipo2-J3 and lipo3-
J3 were distinct from each other, indicating that their inter-
actions with gp140 were qualitatively different with superior
avidity for lipo3-J3. This implied that a multivalent platform
had been formed with cross-linking or multimerization of
Vhhs. This is not surprising since the absence of the nickel
complex allows the free movement and geometrical ar-
rangement of J3-lipid complex within the lipid liposome
membrane so permitting the formation of multivalent lipo-
somal Vhh constructs through cross-linking the envelope
a b
Fig. 6 Antiviral effect of different liposomal formulations and free Vhhs. a Dose-response curves for the antiviral effect of different liposomal formulations
and free Vhhs. b Comparison of calculated EC50 of each liposomal formulation and free J3. Liposome preparations were pre-incubated with TZM-bl cells
for 2 h before virus was added and incubated for 48 h. Values are means ± standard deviations of three replicate measurements in one representative
experiment of three independent experiments. *From one-way ANOVA, significant differences (p< 0.001) in EC50 were observed between lipo3-J3 and the
other liposome formulations or free Vhhs
a b
Fig. 7 Antiviral effect of different liposomal formulations and free dapivirine. a Dose-response curves for the antiviral effect of different liposomal
formulations and free dapivirine. b Comparison of calculated EC50 of each liposomal formulation and free dapivirine. Liposome preparations were
pre-incubated with TZM-bl cells for 2 h before virus was added and incubated for 48 h. Values are means ± standard deviations of three replicate
measurements in one representative experiment of three independent experiments. *From one-way ANOVA, significant differences (p < 0.001) in
EC50 were observed between free dapivirine and the liposomal dapivirine. Dapi: dapivirine
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spikes which are sparsely distributed on the virion surface
and remained static over the time periods. Unexpectedly,
the antiviral potency of lipo3-J3 was remarkably reduced as
evaluated in the antiviral assay compared to lipo1-J3, lipo2-
J3 or free J3, the EC50 for lipo3-J3 being approximately
four times higher than that for lipo2-J3 or free J3. We
hypothesize that in the case of non-covalent linkage, J3
was dissociated from liposome after it bound to gp140
on the virion surface because the interaction between
J3 and gp140 was so strong (K ≅ 10−9 M ~ 10−12 M
compared to K ≅ 10−5 M ~ 10−6 M for attachment to
the nickel-chelating lipid) [32, 40, 43], that J3 was
pulled apart from the nickel complex inserted in the
liposome membrane. The remaining surface antibody
molecules were now free to react with further virus,
the net effect being that lipo2-J3 neutralized the virus
as efficiently as free J3. Although the covalent attachment
of the J3 in lipo3 enhanced lipo3-J3-gp140 interaction, this
fixed the viruses to the surface of the liposome and due to
the comparability in size of the interacting particles, the
number bound to the liposome surface will be restricted
and the small number of viral spikes involved will leave a
large fraction of the antibodies remaining uncombined
which were otherwise available in the non-covalently
linked constructs.
In addition to the neutralization capacity of antibody-
coated liposomes, we investigated whether the liposomes
could have the extra-function of delivering antiviral
drugs intracellularly, in particular using high doses of
otherwise poorly soluble hydrophobic drugs whose encap-
sulation in the liposome would limit its general toxicity.
All of these dapivirine containing liposomes revealed
higher efficacy in reducing viral replication than free dapi-
virine, although no significant differences were observed
between them i.e. irrespective of the presence of irrelevant
or J3 Vhh on the surface. This suggested that the antiviral
activities of J3 were masked by the high dose of dapivirine
and that the liposome platform per se is an efficient deliv-
ery system for dapivirine.
Conclusions
This study demonstrated that antibody-conjugated lipo-
somes can provide anti-HIV viral defence in two ways.
First, non-covalently conjugated liposomal J3 neutralized
HIV virus as efficiently as free J3. It was also shown that
incorporation of the lipophilic drug dapivirine in lipo-
somes resulted in a higher level of virus inactivation in
vitro than observed after exposure of cells to free drug
dissolved in DMSO—an effective method of solubilizing
the drug, but not one which can be used in vivo. Since
we have demonstrated that immunoliposomes with co-
valently grafted anti-CD4 Vhhs facilitated cellular uptake
of liposomes by lymphoma cells overexpressing CD4 on
the surface (data not shown), it follows that a combined
liposome platform encapsulating dapivirine with non-
covalently attached J3 and covalently linked anti-CD4
Vhh could be a powerful potential candidate for HIV
prevention where J3 neutralizes free virus and dissoci-
ates from liposome while the anti-CD4 Vhh coated lipo-
some efficiently delivers the antiviral drug to HIV target
cells overexpressing CD4.
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